INTRODUCTION: The role of surgery in addition to chemotherapy and radiation for stage IIIA non-small-cell lung cancer (NSCLC) remains controversial. Because there are limited data on the benefit from surgery in this setting, we evaluated the use of combined modality therapy nationally and explored the outcomes with and without the addition of surgery. METHODS: Patient variables and treatment-related outcomes were abstracted for patients with clinical stage IIIA NSCLC from the National Cancer Database. Patients receiving chemotherapy and radiation were compared with those undergoing chemotherapy, radiation, and surgery (CRS) in any sequence. RESULTS: Between 1998 and 2010, 61,339 patients underwent combined modality treatment for clinical stage IIIA NSCLC. Of these, 51,979 (84.7%) received chemotherapy and radiation while 9360 (15.3%) underwent CRS. Patients in the CRS group were younger, more likely female patients and Caucasians, and had smaller tumors and lower Charlson comorbidity scores. The 30-day surgical mortality was 200 of 8993 (2.2%). The median overall survival favored the CRS group in both unmatched (32.4 months versus 15.7 months, p < 0.001) and matched analysis based on patient characteristics (34.3 versus 18.4 months, p < 0.001). CONCLUSIONS: There is significant heterogeneity in the treatment of stage IIIA NSCLC in the United States. Patients selected for surgery in addition to chemoradiation therapy seem to have better long-term survival.
INTRODUCTION: The role of surgery in addition to chemotherapy and radiation for stage IIIA non-small-cell lung cancer (NSCLC) remains controversial. Because there are limited data on the benefit from surgery in this setting, we evaluated the use of combined modality therapy nationally and explored the outcomes with and without the addition of surgery. METHODS:Patient variables and treatment-related outcomes were abstracted for patients with clinical stage IIIA NSCLC from the National Cancer Database. Patients receiving chemotherapy and radiation were compared with those undergoing chemotherapy, radiation, and surgery (CRS) in any sequence. RESULTS: Between 1998 and 2010, 61,339 patients underwent combined modality treatment for clinical stage IIIA NSCLC. Of these, 51,979 (84.7%) received chemotherapy and radiation while 9360 (15.3%) underwent CRS. Patients in the CRS group were younger, more likely female patients and Caucasians, and had smaller tumors and lower Charlson comorbidity scores. The 30-day surgical mortality was 200 of 8993 (2.2%). The median overall survival favored the CRS group in both unmatched (32.4 months versus 15.7 months, p < 0.001) and matched analysis based on patient characteristics (34.3 versus 18.4 months, p < 0.001). CONCLUSIONS: There is significant heterogeneity in the treatment of stage IIIA NSCLC in the United States. Patients selected for surgery in addition to chemoradiation therapy seem to have better long-term survival.
Authors: C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman Journal: Cancer Date: 1987-06-01 Impact factor: 6.860
Authors: Julie E Bauman; Michael S Mulligan; Renato G Martins; Brenda F Kurland; Keith D Eaton; Douglas E Wood Journal: Ann Thorac Surg Date: 2008-11 Impact factor: 4.330
Authors: Karl L Uy; Gail Darling; Wei Xu; Qi-Long Yi; Marc De Perrot; Andrew F Pierre; Thomas K Waddell; Michael R Johnston; Andrea Bezjak; Frances A Shepherd; Shaf Keshavjee Journal: J Thorac Cardiovasc Surg Date: 2007-07 Impact factor: 5.209
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Hale B Caglar; Elizabeth H Baldini; Megan Othus; Michael S Rabin; Raphael Bueno; David J Sugarbaker; Steven J Mentzer; Pasi A Jänne; Bruce E Johnson; Aaron M Allen Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Pamela Samson; Aalok Patel; Cliff G Robinson; Daniel Morgensztern; Su-Hsin Chang; Graham A Colditz; Saiama Waqar; Traves D Crabtree; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-08-25 Impact factor: 4.330
Authors: Maja Guberina; Wilfried Eberhardt; Martin Stuschke; Thomas Gauler; Clemens Aigner; Martin Schuler; Georgios Stamatis; Dirk Theegarten; Walter Jentzen; Ken Herrmann; Christoph Pöttgen Journal: Eur J Nucl Med Mol Imaging Date: 2019-02-01 Impact factor: 9.236
Authors: Pamela Samson; Traves D Crabtree; Cliff G Robinson; Daniel Morgensztern; Stephen Broderick; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2017-01-19 Impact factor: 4.330
Authors: Pamela Samson; Aalok Patel; Traves D Crabtree; Daniel Morgensztern; Cliff G Robinson; Graham A Colditz; Saiama Waqar; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-07-28 Impact factor: 4.330
Authors: Stephen R Broderick; Aalok P Patel; Traves D Crabtree; Jennifer M Bell; Daniel Morgansztern; Clifford G Robinson; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-09-26 Impact factor: 4.330
Authors: Elizabeth A David; Robert J Canter; Yingjia Chen; David T Cooke; Rosemary D Cress Journal: Ann Thorac Surg Date: 2016-06-09 Impact factor: 4.330